328 related articles for article (PubMed ID: 23874106)
1. Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.
Maric G; Rose AA; Annis MG; Siegel PM
Onco Targets Ther; 2013; 6():839-52. PubMed ID: 23874106
[TBL] [Abstract][Full Text] [Related]
2. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer.
Rose AA; Grosset AA; Dong Z; Russo C; Macdonald PA; Bertos NR; St-Pierre Y; Simantov R; Hallett M; Park M; Gaboury L; Siegel PM
Clin Cancer Res; 2010 Apr; 16(7):2147-56. PubMed ID: 20215530
[TBL] [Abstract][Full Text] [Related]
3. EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer.
Yardley DA; Weaver R; Melisko ME; Saleh MN; Arena FP; Forero A; Cigler T; Stopeck A; Citrin D; Oliff I; Bechhold R; Loutfi R; Garcia AA; Cruickshank S; Crowley E; Green J; Hawthorne T; Yellin MJ; Davis TA; Vahdat LT
J Clin Oncol; 2015 May; 33(14):1609-19. PubMed ID: 25847941
[TBL] [Abstract][Full Text] [Related]
4. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent.
Marquez-Nostra BV; Lee S; Laforest R; Vitale L; Nie X; Hyrc K; Keler T; Hawthorne T; Hoog J; Li S; Dehdashti F; Ma CX; Lapi SE
Oncotarget; 2017 Nov; 8(61):104303-104314. PubMed ID: 29262642
[TBL] [Abstract][Full Text] [Related]
5. Management of metastatic breast cancer with second-generation antibody-drug conjugates: focus on glembatumumab vedotin (CDX-011, CR011-vcMMAE).
Vaklavas C; Forero A
BioDrugs; 2014 Jun; 28(3):253-63. PubMed ID: 24496926
[TBL] [Abstract][Full Text] [Related]
6. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
[TBL] [Abstract][Full Text] [Related]
7. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Billups CA; Hawthorne T; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2014 Oct; 61(10):1816-21. PubMed ID: 24912408
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.
Bendell J; Saleh M; Rose AA; Siegel PM; Hart L; Sirpal S; Jones S; Green J; Crowley E; Simantov R; Keler T; Davis T; Vahdat L
J Clin Oncol; 2014 Nov; 32(32):3619-25. PubMed ID: 25267761
[TBL] [Abstract][Full Text] [Related]
9. Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.
Rose AAN; Biondini M; Curiel R; Siegel PM
Pharmacol Ther; 2017 Nov; 179():127-141. PubMed ID: 28546082
[TBL] [Abstract][Full Text] [Related]
10. Gpnmb/osteoactivin: an indicator and therapeutic target in tumor and nontumorous lesions.
Zhuo H; Zhou L
Pharmazie; 2016 Oct; 71(10):555-561. PubMed ID: 29441921
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibitors induce GPNMB cell-surface expression by modulating lysosomal positioning and sensitize breast cancer cells to glembatumumab vedotin.
Biondini M; Kiepas A; El-Houjeiri L; Annis MG; Hsu BE; Fortier AM; Morin G; Martina JA; Sirois I; Aguilar-Mahecha A; Gruosso T; McGuirk S; Rose AAN; Tokat UM; Johnson RM; Sahin O; Bareke E; St-Pierre J; Park M; Basik M; Majewski J; Puertollano R; Pause A; Huang S; Keler T; Siegel PM
Oncogene; 2022 Mar; 41(12):1701-1717. PubMed ID: 35110681
[TBL] [Abstract][Full Text] [Related]
12. Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma.
Roth M; Barris DM; Piperdi S; Kuo V; Everts S; Geller D; Houghton P; Kolb EA; Hawthorne T; Gill J; Gorlick R
Pediatr Blood Cancer; 2016 Jan; 63(1):32-8. PubMed ID: 26305408
[TBL] [Abstract][Full Text] [Related]
13. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Naumovski L; Junutula JR
Curr Opin Mol Ther; 2010 Apr; 12(2):248-57. PubMed ID: 20373269
[TBL] [Abstract][Full Text] [Related]
14. GPNMB expression in uveal melanoma: a potential for targeted therapy.
Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
[TBL] [Abstract][Full Text] [Related]
15. Glycoprotein Non-Metastatic Melanoma Protein B (GPNMB) and Cancer: A Novel Potential Therapeutic Target.
Taya M; Hammes SR
Steroids; 2018 May; 133():102-107. PubMed ID: 29097143
[TBL] [Abstract][Full Text] [Related]
16. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy.
Zhou LT; Liu FY; Li Y; Peng YM; Liu YH; Li J
Neoplasma; 2012; 59(1):1-5. PubMed ID: 22017590
[TBL] [Abstract][Full Text] [Related]
17. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer.
Keir CH; Vahdat LT
Expert Opin Biol Ther; 2012 Feb; 12(2):259-63. PubMed ID: 22229970
[TBL] [Abstract][Full Text] [Related]
18. ADAM10 releases a soluble form of the GPNMB/Osteoactivin extracellular domain with angiogenic properties.
Rose AA; Annis MG; Dong Z; Pepin F; Hallett M; Park M; Siegel PM
PLoS One; 2010 Aug; 5(8):e12093. PubMed ID: 20711474
[TBL] [Abstract][Full Text] [Related]
19. Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer ("METRIC"): a randomized multicenter study.
Vahdat LT; Schmid P; Forero-Torres A; Blackwell K; Telli ML; Melisko M; Möbus V; Cortes J; Montero AJ; Ma C; Nanda R; Wright GS; He Y; Hawthorne T; Bagley RG; Halim AB; Turner CD; Yardley DA
NPJ Breast Cancer; 2021 May; 7(1):57. PubMed ID: 34016993
[TBL] [Abstract][Full Text] [Related]
20. Glycoprotein nonmetastatic melanoma protein B: A key mediator and an emerging therapeutic target in autoimmune diseases.
Tsou PS; Sawalha AH
FASEB J; 2020 Jul; 34(7):8810-8823. PubMed ID: 32445534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
